Toleranzia AB (publ): Receives approximately SEK 42 million through fully subscribed directed share issue
21 September - 2021
Toleranzia AB (publ) (”Toleranzia” or the ”Company”) today announces the outcome of the directed share issue resolved upon by the extraordinary general meeting on 16 September 2021, consisting of not more than 31,818,183 shares at a subscription price of SEK 1.32 per share (the “Share Issue”). The Share Issue was directed to Flerie Invest AB, which is controlled by Thomas Eldered, as well as Nordic Tender Aktiebolag, which is controlled by Lars Molinder. Flerie Invest AB has subscribed and been allocated 30,303,031 shares, corresponding to approximately SEK 40 million. Nordic Tender Aktiebolag has subscribed and been allocated 1,515,152 shares, corresponding to approximately SEK 2 million. The Share Issue has thus been fully subscribed and the Company will receive SEK 42 million before transaction-related costs.
“We thank the new owners for the confidence they have shown in Toleranzia. It is particularly satisfying to gain the interest of reputable industry investors. We see that with this directed issue we will have a long-term ownership base that will be very important for the growth of the company. With this important capital injection, we will have a strong financial platform to drive the clinical development of our first drug in the field of rare autoimmune diseases with high intensity”, comments Toleranzia’s CEO, Charlotte Fribert.
The Share Issue, which the extraordinary general meeting resolved upon on 16 September 2021, was directed to Flerie Invest AB, controlled by Thomas Eldered, as well as Nordic Tender Aktiebolag, controlled by Lars Molinder. Flerie Invest AB has subscribed and been allocated 30,303,031 shares, equivalent to approximately SEK 40 million, and Nordic Tender Aktiebolag has subscribed and been allocated 1,515,152 shares, equivalent to approximately SEK 2 million. Due to the high exercise rate of warrants of series TO3, which was announced through press release yesterday, Flerie Invest AB has been able to fully subscribe without triggering any mandatory bid obligations. Thus, the Share Issue has been fully subscribed.
The net proceeds from the Share Issue are intended to be used to increase the resources to the planned phase I/IIa-study for the Company’s drug candidate, TOL2 – a potential cure for the autoimmune disease myasthenia gravis.
Through the Share Issue, the Company’s share capital will increase by SEK 3,977,272.875 through issue of 31,818,183 new shares. The subscription price in the Share Issue of SEK 1.32 corresponds to the volume-weighted average price (VWAP) in the Company’s share during the period 27 July 2021 up to and including 9 August 2021 on Nasdaq First North Growth Market and is deemed to reflect current market conditions and demand. The reasons for the deviation from the shareholders’ preferential rights are to provide the Company with strategically important shareholders and to carry out a capital raise in a timely and cost-effective manner.
After registration of the new shares in Share Issue as well as the new shares following the exercise of warrants of series TO3, the Company’s share capital will amount to 13,789,403.875 SEK divided into 110,315,231 shares. The Share Issue results in a dilution for existing shareholders of approximately 28.8 percent.
Eversheds Sutherland Advokatbyrå AB is legal advisor to Toleranzia in connection with the Share Issue.
For further information, please contact:
Charlotte Fribert – CEO, Toleranzia
Telephone: +46 763 19 98 98
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can alleviate or cure the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08 503 015 50, CA@mangold.se, is the Company’s Certified Adviser.